Cargando…

Place of death and other factors associated with unnatural mortality in patients with serious mental disorders: population-based retrospective cohort study

BACKGROUND: Patients with serious mental disorders have poorer healthcare outcomes at the end of life and are at greater risk of dying from unnatural causes. AIMS: To explore place of death and demographic and clinical correlates of unnatural causes of death in patients with serious mental disorders...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Rebecca, Gaughran, Fiona, Whitburn, Tara, Higginson, Irene J., Gao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401542/
https://www.ncbi.nlm.nih.gov/pubmed/31068233
http://dx.doi.org/10.1192/bjo.2019.5
Descripción
Sumario:BACKGROUND: Patients with serious mental disorders have poorer healthcare outcomes at the end of life and are at greater risk of dying from unnatural causes. AIMS: To explore place of death and demographic and clinical correlates of unnatural causes of death in patients with serious mental disorders. METHOD: Routinely collected patient data were used to explore bivariate and adjusted associations between covariates and natural/unnatural cause of death. RESULTS: In multivariable analysis (n = 1029), dying at home (odds ratio (OR) = 1.87, 95% CI 1.03–3.40), ‘other’ locations (OR = 16.50, 95% CI 7.57–36.00), younger age (OR = 17.26, 95% CI 8.28–36.00) and a diagnosis other than schizophrenia spectrum disorder (OR = 1.69, 95% CI 1.04–2.73) were correlates of unnatural cause of death. CONCLUSIONS: Deaths from unnatural causes were high and more likely to occur at home and non-healthcare settings. Unnatural causes of death were higher in younger patients with non-schizophrenia spectrum disorder diagnoses. DECLARATION OF INTEREST: F.G. has received support or honoraria for CME, advisory work and lectures from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche, and Sunovion, and has a family member with professional links to Lilly and GSK, including shares.